199 related articles for article (PubMed ID: 15642953)
1. Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response.
Milani V; Frankenberger B; Heinz O; Brandl A; Ruhland S; Issels RD; Noessner E
Int Immunol; 2005 Mar; 17(3):257-68. PubMed ID: 15642953
[TBL] [Abstract][Full Text] [Related]
2. Melanoma cells present high levels of HLA-A2-tyrosinase in association with instability and aberrant intracellular processing of tyrosinase.
Michaeli Y; Sinik K; Haus-Cohen M; Reiter Y
Eur J Immunol; 2012 Apr; 42(4):842-50. PubMed ID: 22531911
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
[TBL] [Abstract][Full Text] [Related]
4. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.
Michaeli Y; Denkberg G; Sinik K; Lantzy L; Chih-Sheng C; Beauverd C; Ziv T; Romero P; Reiter Y
J Immunol; 2009 May; 182(10):6328-41. PubMed ID: 19414786
[TBL] [Abstract][Full Text] [Related]
5. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.
Castelli C; Ciupitu AM; Rini F; Rivoltini L; Mazzocchi A; Kiessling R; Parmiani G
Cancer Res; 2001 Jan; 61(1):222-7. PubMed ID: 11196165
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of acute and permanent heat shock protein 70 overexpression in tumor cells on lysability by cytotoxic T lymphocytes.
Dressel R; Grzeszik C; Kreiss M; Lindemann D; Herrmann T; Walter L; Günther E
Cancer Res; 2003 Dec; 63(23):8212-20. PubMed ID: 14678977
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
8. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
[TBL] [Abstract][Full Text] [Related]
9. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
[TBL] [Abstract][Full Text] [Related]
10. Acute extracellular acidification reduces intracellular pH, 42 degrees C-induction of heat shock proteins and clonal survival of human melanoma cells grown at pH 6.7.
Coss RA; Storck CW; Wachsberger PR; Reilly J; Leeper DB; Berd D; Wahl ML
Int J Hyperthermia; 2004 Feb; 20(1):93-106. PubMed ID: 14612316
[TBL] [Abstract][Full Text] [Related]
11. Interaction of human heat shock protein 70 with tumor-associated peptides.
Pandya MJ; Bendz H; Manzenrieder F; Noessner E; Kessler H; Buchner J; Issels RD
Biol Chem; 2009 Apr; 390(4):305-12. PubMed ID: 19199830
[TBL] [Abstract][Full Text] [Related]
12. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
[TBL] [Abstract][Full Text] [Related]
13. Effects of thermal stress on tumor antigenicity and recognition by immune effector cells.
Milani V; Noessner E
Cancer Immunol Immunother; 2006 Mar; 55(3):312-9. PubMed ID: 16151807
[TBL] [Abstract][Full Text] [Related]
14. Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells.
Glazyrin AL; Kan-Mitchell J; Mitchell ML
Cancer Immunol Immunother; 2003 Mar; 52(3):171-8. PubMed ID: 12649746
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 70: role in antigen presentation and immune stimulation.
Milani V; Noessner E; Ghose S; Kuppner M; Ahrens B; Scharner A; Gastpar R; Issels RD
Int J Hyperthermia; 2002; 18(6):563-75. PubMed ID: 12537755
[TBL] [Abstract][Full Text] [Related]
16. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.
Sørensen RB; Junker N; Kirkin A; Voigt H; Svane IM; Becker JC; thor Straten P; Andersen MH
Cancer Immunol Immunother; 2009 May; 58(5):665-75. PubMed ID: 18828018
[TBL] [Abstract][Full Text] [Related]
17. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.
Robbins PF; el-Gamil M; Kawakami Y; Stevens E; Yannelli JR; Rosenberg SA
Cancer Res; 1994 Jun; 54(12):3124-6. PubMed ID: 8205528
[TBL] [Abstract][Full Text] [Related]
18. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5.
Sensi M; Pietra G; Molla A; Nicolini G; Vegetti C; Bersani I; Millo E; Weiss E; Moretta L; Mingari MC; Anichini A
Int Immunol; 2009 Mar; 21(3):257-68. PubMed ID: 19181932
[TBL] [Abstract][Full Text] [Related]
19. Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70.
Koide T; Iinuma H; Fukushima R
Oncol Rep; 2009 Mar; 21(3):737-46. PubMed ID: 19212634
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
